A Qualitative Transcriptional Signature for Predicting Extreme Resistance of ER-Negative Breast Cancer to Paclitaxel, Doxorubicin, and Cyclophosphamide Neoadjuvant Chemotherapy

For estrogen receptor (ER)-negative breast cancer patients, paclitaxel (P), doxorubicin (A) and cyclophosphamide (C) neoadjuvant chemotherapy (NAC) is the standard therapeutic regimen. Pathologic complete response (pCR) and residual disease (RD) are common surrogate measures of chemosensitivity. Aft...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Front Mol Biosci
Autori principali: Chen, Yanhua, Cai, Hao, Chen, Wannan, Guan, Qingzhou, He, Jun, Guo, Zheng, Li, Jing
Natura: Artigo
Lingua:Inglês
Pubblicazione: Frontiers Media S.A. 2020
Soggetti:
Molecular Biosciences
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7109260/
https://ncbi.nlm.nih.gov/pubmed/32269999
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmolb.2020.00034
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi